



2022 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting (Barcelona, Spain and Virtual): Eisai Oral Presentations and Posters

Please see the Eisai oral presentations and posters presented at the 2022 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) annual meeting listed below.

LECANEMAB (BAN2401)

1. Bateman R and McDade E. Biomarker Results from the Lecanemab Phase 2 Study: Linking Disease Progression to Chronic Amyloid Treatment. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual
2. Cabal A, Geerts H, Walker M, et al. Quantitative Systems Pharmacology Amyloid Platform: Multiscale Computational Modeling of A β Biology and Its Interaction with Lecanemab Pharmacology. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual
3. Charil A, Krause S, Kanekiyo M, et al. Baseline Tau PET in CLARITY AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401) in Early Alzheimer's Disease. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual
4. Irizarry M. Update on Lecanemab Clinical Development Including New Subcutaneous (SC) Formulation. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual
5. Lannfelt L. Science of the Amyloid- β Cascade and Distinct Mechanisms of Action of Lecanemab. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

6. Sabbagh MN. Key Trial Design Aspects and Clinical Outcomes of the Lecanemab Phase 2 Trial and Open-Label Extension in Early Alzheimer's Disease. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

General AD

1. Wang Y, Li M, Berlowitz D, et al. Clinical Transition to Alzheimer's Disease and Predictors in Individuals with Mild Cognitive Impairment. Poster presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual
2. Yamashita K, Miura M, Watanabe S, et al. Fully Automated Plasma β -Amyloid Immunoassays Predict Amyloid Pathology Defined by Amyloid PET. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

Elenbecestat

1. Bullich S, Mueller A, De Santi S, et al. Evaluation of Tau Deposition in Amyloid-Positive MCI and Mild-AD Dementia Subjects from the Mission AD Program Using ^{18}F -PI-2620. Poster presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

E2511

1. Tomioka T, Moriyama Y, Hiramatsu N, et al. E2511, A Novel Small Compound TRKA Biased Positive Allosteric Modulator, Reinnervates Cholinergic Neuron Via Enhancement of Specific Trophic Signaling of TRKA IN Non-Clinical Studies. Poster presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

E2814

1. Aceves P, Yagi T, Boyd P, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of the Novel Anti-Tau Therapeutic Antibody E2814: A Phase 1, First-In-Human (FIH) Study in Healthy Volunteers. Oral presentation presented at: International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD) Annual Meeting; March 15 - 20, 2022; Barcelona, Spain and Virtual

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the oral presentations or poster(s) listed above, please submit your request via

www.eisaimedicalinformation.com/neurology/medicalinquiry or the Submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Oral Presentation/Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_medinfo@eisai.com or call 1-888-274-2378.